The Social Check-up

21 March 2018

Ogilvy Healthworld's fourth annual report analyzing social media usage across pharma reveals that Novo Nordisk (NOV: N), Johnson & Johnson (NYSE: JNJ) and Novartis (NOVN: VN) are leading the charge.

The report, put together with social media analytics specialist Pulsar, is entitled The Social Check-up and looks at 20 leading pharmaceutical companies and how they are producing content, their posting behavior and their weighted1 engagement scores.

“The Social Check-up reveals a growing maturity in pharma’s use of social channels, since our first report in 2014, reflecting increasing confidence and experience in the social space,” explains Ogilvy Healthworld’s social media director, Chloe Partikas.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK